Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 104Neoplasms 13Neoplasm Metastasis 8Sarcoma 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Lung Neoplasms 4Liposarcoma 4Multiple Myeloma 3Head and Neck Neoplasms 3Glioblastoma 3Endometrial Neoplasms 3Colonic Neoplasms 3Breast Diseases 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm, Residual 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Inflammation 2Estrogen Receptor-positive Breast Cancer 2Esophageal Squamous Cell Carcinoma 2

Interventions

temsirolimus 1sintilimab 1pembrolizumab 1palbociclib 1olaparib 1durvalumab 1defactinib 1copanlisib 1ceralasertib 1Therapeutics 1Restraint, Physical 1Radiation, Ionizing 1RO5126766 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Hysterectomy 1Fulvestrant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Endometrioid × palbociclib × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡